Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
Merck received FDA approval for LIPFENDRA, the first and only once-daily oral PCSK9 inhibitor to reduce LDL-C in adults with hypercholesterolemia. The approval is based on the CORALreef Lipids and HeFH Phase 3 trials, which showed placebo-adjusted LDL-C reductions of 56% and 59% respectively at week 24.
Key figures
- Drug Name
- LIPFENDRA (enlicitide)
- Phase Of Trial
- Phase 3
- Ldlc reduction coralreef hefh
- 59%
- Ldlc reduction coralreef lipids
- 56%
- Trial enrollment coralreef hefh
- 303
- Trial enrollment coralreef lipids
- 2904
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.